Biogen’s Aduhelm rollout goes from bad to worse
pharmaphorum
OCTOBER 21, 2021
Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. billion, with Tecfidera’s decline offset in part by gains for follow-up drug Vumerity (diroximel fumarate), which brought in $121 million. That dragged down Biogen’s overall revenues, which fell 18% to $2.2
120 
Let's personalize your content